Publication | Closed Access
Frequent <i><scp>COL4</scp></i> mutations in familial microhematuria accompanied by later‐onset Alport nephropathy due to focal segmental glomerulosclerosis
39
Citations
39
References
2017
Year
Glomerular DiseaseGeneticsRenal PathologyGenetic EpidemiologyPathologyDisease Gene IdentificationClinical GeneticsGlomerulonephritisMendelian DisorderIga GlomerulonephritisMolecular DiagnosticsChronic Kidney DiseaseVariant InterpretationFamilial MicrohematuriaFocal Segmental GlomerulosclerosisEnd-stage Renal DiseaseGenetic DisorderFamilial Microscopic HematuriaLater‐onset Alport NephropathyNext Generation SequencingGlomerulopathyMedicineNephrologyKidney ResearchConnective Tissue Disease
Familial microscopic hematuria (FMH) is associated with a genetically heterogeneous group of conditions including the collagen-IV nephropathies, the heritable C3/CFHR5 nephropathy and the glomerulopathy with fibronectin deposits. The clinical course varies widely, ranging from isolated benign familial hematuria to end-stage renal disease (ESRD) later in life. We investigated 24 families using next generation sequencing (NGS) for 5 genes: COL4A3, COL4A4, COL4A5, CFHR5 and FN1. In 17 families (71%), we found 15 pathogenic mutations in COL4A3/A4/A5, 9 of them novel. In 5 families patients inherited classical AS with hemizygous X-linked COL4A5 mutations. Even more patients developed later-onset Alport-related nephropathy having inherited heterozygous COL4A3/A4 mutations that cause thin basement membranes. Amongst 62 heterozygous or hemizygous patients, 8 (13%) reached ESRD, while 25% of patients with heterozygous COL4A3/A4 mutations, aged >50-years, reached ESRD. In conclusion, COL4A mutations comprise a frequent cause of FMH. Heterozygous COL4A3/A4 mutations predispose to renal function impairment, supporting that thin basement membrane nephropathy is not always benign. The molecular diagnosis is essential for differentiating the X-linked from the autosomal recessive and dominant inheritance. Finally, NGS technology is established as the gold standard for the diagnosis of FMH and associated collagen-IV glomerulopathies, frequently averting the need for invasive renal biopsies.
| Year | Citations | |
|---|---|---|
Page 1
Page 1